INBRAIN Neuroelectronics is a spin-off of Graphene Flagship, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, Spain. Since 2019 they have been working on decoding brain signals to design medical solutions for patients with epilepsy, Parkinson’s disease and other neurological disorders, creating small implantable intelligent brain systems that are capable of interpreting brain signals with high fidelity.
The objective is to have a personalized therapeutic response, adapted to each specific patient.
INBRAIN had a significant investment in 2020, and today announces a Series A investment of € 14.35M, one of the largest rounds in the Spanish MedTech industry.
With this investment they will be able to bring the technology to humans using a nanoscale graphene electrode, innovating in a technology that at the moment is based mainly on metals such as platinum and iridium, which impose important restrictions in terms of miniaturization and resolution of the signal. and therefore cause considerable side effects.
Current technology has a 50% rejection rate, but graphene-based technology will improve that number by not relying on metals.
Thanks to nanoscale manufacturing, they will be able to achieve the resolution of a single neuron. Being much smaller, they are safer to implant, but can also be programmed, updated and recharged wirelessly.
Powered by artificial intelligence, the implant can learn from each specific patient’s brain and trigger adaptive responses to deliver personalized neurological therapy. In addition, the use of big data management will allow remote monitoring of the device and data processing.
Large animal studies have already been conducted so far, and the investment will bring the technology to human patients, in collaboration with key neurological and neurosurgical groups in Europe.
You can get more information at inbrain-neuroelectronics.com